Literature DB >> 17213800

Tool from ancient pharmacopoeia prevents vision loss.

Jeffrey H Boatright1, Anisha G Moring, Clinton McElroy, Michael J Phillips, Vi T Do, Bo Chang, Norm L Hawes, Amber P Boyd, Sheree S Sidney, Rachael E Stewart, Steven C Minear, Rajashree Chaudhury, Vincent T Ciavatta, Cecilia M P Rodrigues, Clifford J Steer, John M Nickerson, Machelle T Pardue.   

Abstract

PURPOSE: Bear bile has been used in Asia for over 3,000 years to treat visual disorders, yet its therapeutic potential remains unexplored in Western vision research. The purpose of this study was to test whether treatment of mice undergoing retinal degeneration with tauroursodeoxycholic acid (TUDCA), a primary constituent of bear bile, alters the course of degeneration.
METHODS: Two retinal degeneration models were tested: the rd10 mouse, which has a point mutation in the gene encoding the beta subunit of rod phosphodiesterase, and light induced retinal damage (LIRD). For LIRD studies, albino Balb/C adult mice were subcutaneously injected with TUDCA (500 mg/kg body weight) or vehicle (0.15 M NaHCO(3)). Sixteen h later, each mouse received repeat injections. Half of each treatment group was then placed in bright light (10,000 lux) or dim light (200 lux) for seven h. At the end of exposure, animals were transferred to their regular housing. Electroretinograms (ERGs) were assessed 24 h later, mice sacrificed, eyes embedded in paraffin and sectioned, and retina sections assayed for morphology and apoptosis by TUNEL and anti-active caspase-3 immunoreactivity via fluorescent confocal microscopy. A subset of mice were sacrificed 8 and 15 days after exposure and retina sections analyzed for morphology and apoptosis. For rd10 studies, mice were injected subcutaneously with TUDCA or vehicle at postnatal (P) days 6, 9, 12, and 15. At p18, ERGs were recorded, mice were euthanized and eyes were harvested, fixed, and processed. Retinal sections were stained (toluidine blue), and retinal cell layers morphometrically analyzed by light microscopy. Consecutive sections were analyzed for apopotosis as above.
RESULTS: By every measure, TUDCA greatly slowed retinal degeneration in LIRD and rd10 mice. ERG a-wave and b-wave amplitudes were greater in mice treated with TUDCA compared to those treated with vehicle. Retinas of TUDCA-treated mice had thicker outer nuclear layers, more photoreceptor cells, and more fully-developed photoreceptor outer segments. Finally, TUDCA treatments dramatically suppressed signs of apoptosis in both models.
CONCLUSIONS: Systemic injection of TUDCA, a primary constituent of bear bile, profoundly suppressed apoptosis and preserved function and morphology of photoreceptor cells in two disparate mouse models of retinal degeneration. It may be that bear bile has endured so long in Asian pharmacopeias due to efficacy resulting from this anti-apoptotic and neuroprotective activity of TUDCA. These results also indicate that a systematic, clinical assessment of TUDCA may be warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17213800

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  53 in total

Review 1.  AAV-mediated gene therapy in mouse models of recessive retinal degeneration.

Authors:  J-J Pang; L Lei; X Dai; W Shi; X Liu; A Dinculescu; J H McDowell
Journal:  Curr Mol Med       Date:  2012-03       Impact factor: 2.222

2.  Chemical chaperone TUDCA preserves cone photoreceptors in a mouse model of Leber congenital amaurosis.

Authors:  Tao Zhang; Wolfgang Baehr; Yingbin Fu
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-05       Impact factor: 4.799

3.  Unfolding the Therapeutic Potential of Chemical Chaperones for Age-related Macular Degeneration.

Authors:  Theodor Sauer; Mrinali Patel; Chi-Chao Chan; Jingsheng Tuo
Journal:  Expert Rev Ophthalmol       Date:  2008-02

4.  Retinal expression of Fgf2 in RCS rats with subretinal microphotodiode array.

Authors:  Vincent T Ciavatta; Moon Kim; Paul Wong; John M Nickerson; R Keith Shuler; George Y McLean; Machelle T Pardue
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-05       Impact factor: 4.799

5.  Aerobic exercise protects retinal function and structure from light-induced retinal degeneration.

Authors:  Eric C Lawson; Moon K Han; Jana T Sellers; Micah A Chrenek; Adam Hanif; Marissa A Gogniat; Jeffrey H Boatright; Machelle T Pardue
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

Review 6.  Endoplasmic reticulum stress and the unfolded protein responses in retinal degeneration.

Authors:  Sarah X Zhang; Emily Sanders; Steven J Fliesler; Joshua J Wang
Journal:  Exp Eye Res       Date:  2014-05-02       Impact factor: 3.467

7.  Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration.

Authors:  Brian C Oveson; Takeshi Iwase; Sean F Hackett; Sun Young Lee; Shinichi Usui; Thomas W Sedlak; Solomon H Snyder; Peter A Campochiaro; Jennifer U Sung
Journal:  J Neurochem       Date:  2010-12-02       Impact factor: 5.372

8.  AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation.

Authors:  Ji-Jing Pang; Sanford L Boye; Ashok Kumar; Astra Dinculescu; Wentao Deng; Jie Li; Qiuhong Li; Asha Rani; Thomas C Foster; Bo Chang; Norman L Hawes; Jeffrey H Boatright; William W Hauswirth
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-27       Impact factor: 4.799

9.  Bile acids in treatment of ocular disease.

Authors:  Jeffrey H Boatright; John M Nickerson; Anisha G Moring; Machelle T Pardue
Journal:  J Ocul Biol Dis Infor       Date:  2009-08-27

10.  Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina.

Authors:  Charlotte Andrieu-Soler; Mounia Halhal; Jeffrey H Boatright; Staci A Padove; John M Nickerson; Eva Stodulkova; Rachael E Stewart; Vincent T Ciavatta; Marc Doat; Jean-Claude Jeanny; Therèse de Bizemont; Florian Sennlaub; Yves Courtois; Francine Behar-Cohen
Journal:  Mol Vis       Date:  2007-05-02       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.